Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 14/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.54 |
| ▸ | PDE4A | P27815 | 8/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.54 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6030982 | 0.82 | PDE4B (0.57) | PDE4DPDE4BPDE4APDE4CPDE3B | |
| Hydrochloric Acid SCHEMBL6032043 | 0.76 | PDE4D (0.55) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL5563541 | 0.72 | PDE7B (0.79) | PDE4DPDE4BPDE4APDE4CPDE3B | |
| SCHEMBL5565387 | 0.72 | PDE7B (0.79) | PDE4DPDE4BPDE4APDE4CPDE3B | |
| SCHEMBL5563545 | 0.72 | PDE7B (0.79) | PDE4DPDE4BPDE4APDE4CPDE3B | |
| SCHEMBL6479899 | 0.71 | PDE4D (0.74) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL6032301 | 0.70 | PDE4B (0.64) | PDE4DPDE4BPDE4APDE4CPDE3B | |
| SCHEMBL14251169 | 0.70 | PDE4D (0.73) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL6485199 | 0.69 | PDE4D (0.71) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL6485190 | 0.69 | PDE4D (0.71) | PDE4DPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167001-A1 | Pyridazinone-derivatives as pde4 inhibitors | ALTANA PHARMA AG (DE) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167001-A1 | Pyridazinone-derivatives as pde4 inhibitors | PDE4A, PDE3A, PDE4B | PDE4D 8/4885PDE4B 3/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.